Original Article A three-miRNA signature as a potential biomarker for the diagnosis of glioma

Wu Xu, Weibang Liang, Yuxiang Dai
2017 Int J Clin Exp Pathol   unpublished
Aim: Biomarkers in blood have become increasingly appreciated in the diagnosis of gliomas. As the involvement of microRNAs (miRNAs) in carcinogenesis is well known, we conducted this study to identify differentially expressed miRNAs in blood samples of glioma patients to assess their diagnostic value. Method: Here, a total of 47 glioma patients and 45 healthy volunteers were enrolled from a hospital. Total RNA was isolated from plasma using TRIzol reagent and miRNA profiles of gliomas were
more » ... ned using miRNA microarrays. The performance of three selected miRNAs as cancer markers was analyzed by reverse transcription-PCR (RT-PCR). A new miRNA-based score was conducted by the logistic regression model. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) was generated to assess the diagnostic values of the miRNAs. Results: Microarray data showed 13 cases of aberrant expression of miRNAs. Among these, expression levels of miR-17, miR-130a, and miR-10b were markedly increased in the plasma of gliomas compared to in healthy individuals (all P<0.01). The AUC (95% CI) of miR-17, miR-130a, and miR-10b was 0.78 (0.69-0.86), 0.72 (0.62-0.81), 0.72 (0.62-0.80), respectively. We conducted a new score named the miR-Score, based on three selected miRNAs: miR-Score=-5.0+0.55*miR-17+0.40* miR-130a+0.20*miR-10b, which had the best diagnostic ability performance with AUC of 0.87 (0.78-0.93), sensitivity of 72.3%, and specificity of 85.1%. Conclusion: The three selected miRNAs are significantly increased in the plasma of glioma patients and thus have great potential to be novel, sensitive, and reliable biomarkers for the diagnosis of gliomas.